Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Nanosonics Limited ( (AU:NAN) ).
Nanosonics Limited has appointed Sarah Butler as an independent non-executive director, effective 19 January 2026, strengthening its board with extensive international experience in healthcare, strategy, profitable growth and SaaS. Butler, a former senior partner at Booz Allen Hamilton, Booz & Company and PwC where she led a AU$2 billion Global Health practice, currently sits on several healthcare and insurance-related boards and will also join Nanosonics’ Innovation and Development Committee, a move expected to support the company’s innovation agenda and global expansion in infection prevention and endoscope reprocessing.
The most recent analyst rating on (AU:NAN) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
More about Nanosonics Limited
Nanosonics Limited is an Australian-listed medical technology company specialising in infection prevention solutions for healthcare settings. The company develops and commercialises innovative disinfection technologies and is expanding its focus into endoscope reprocessing, targeting global healthcare markets across Asia-Pacific, Europe and the Americas.
YTD Price Performance: 2.02%
Average Trading Volume: 417,324
Technical Sentiment Signal: Sell
Current Market Cap: A$1.23B
For a thorough assessment of NAN stock, go to TipRanks’ Stock Analysis page.